SCHEMBL2892883

SCHEMBL2892883

COCCCNc1cc(C(C)C)ncc1C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 2/20 0.38
HCAR3 P49019 2/20 0.38
KDM4C Q9H3R0 2/20 0.38
KDM6B O15054 1/20 0.38
KDM4E B2RXH2 2/20 0.37
ASPH Q12797 2/20 0.37
RIOX2 Q8IUF8 2/20 0.37
KDM8 Q8N371 2/20 0.37
ALDH1A1 P00352 3/20 0.36
HPGD P15428 1/20 0.36
IRAK4 Q9NWZ3 2/20 0.36
TNF P01375 1/20 0.36
CISD1 Q9NZ45 2/20 0.36
EGLN1 Q9GZT9 1/20 0.36
MAPK1 P28482 2/20 0.36
JAK3 P52333 1/20 0.35
KMT2A Q03164 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2902554 0.86 PTGER4 (0.50) PTGER4KDM4EALDH1A1HPGDMAPK1
SCHEMBL2894358 0.75 JAK3 (0.44) HCAR3KDM4EALDH1A1HPGDMAPK1
SCHEMBL3640375 0.71 KDM4E (0.49) PTGER4HCAR3KDM4CKDM6BKDM4E
SCHEMBL11083556 0.70 MERTK (0.47) HCAR3ALDH1A1HPGDMAPK1JAK3
SCHEMBL17075530 0.67 HCAR3 (0.55) PTGER4HCAR3ALDH1A1HPGDKMT2A
SCHEMBL19706323 0.67 GABRP (0.58) KDM4EASPHKDM8ALDH1A1HPGD
SCHEMBL18272540 0.67 PTGER4 (0.56) PTGER4HCAR3KDM4EALDH1A1HPGD
SCHEMBL12316423 0.67 TDP1 (0.45) KDM4EALDH1A1HPGDKMT2AHTT
SCHEMBL2902606 0.67 REN (0.46) HCAR3KDM4EALDH1A1JAK3KMT2A
SCHEMBL22861816 0.65 KDM4E (0.45) HCAR3KDM4EASPHRIOX2KDM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2202228-B1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL (JP) 2014-12-10 EP disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
EP-2202228-A1 AMIDE COMPOUNDS AND USE OF THE SAME Takeda Pharmaceutical Company Limited (JP) 2010-06-30 EP disclosed
EP-2202228-A1 AMIDE COMPOUNDS AND USE OF THE SAME Takeda Pharmaceutical Company Limited (JP) 2010-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME REN, ACE, AGT PTGER4 597/4885HCAR3 1369/4885KDM4C 1170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.